Who Needs Rehab When You Have Ozempic

A friend recently told me that one of her coworkers stopped drinking. She didn’t go through AA or therapy. She didn’t have some moment of clarity at 3 AM. She started Ozempic for weight loss, and a few weeks in, she just stopped wanting wine. Didn't think about it. Didn't miss it. The nightly bottle of pinot that simply lost its pull.

"So I was wondering," she said, "if maybe I should just try that instead of enrolling in an IOP?"

It was a fair question. It also captured everything that is both exciting and deeply concerning about the GLP-1 conversation happening right now.

The Research on GLP-1’s & Addiction

The first randomized clinical trial of semaglutide for alcohol use disorder found that even low-dose semaglutide reduced how much people drank during a controlled lab procedure and lowered their reported cravings compared to a placebo. A separate Swedish study tracked 227,886 people with alcohol use disorder and found that periods of GLP-1 agonist use were associated with significantly fewer alcohol-related hospitalizations. The effect was strongest for semaglutide, and the reductions were larger than what existing AUD medications typically produce.

There’s clearly something there.

Why It Works (Probably)

Your brain has GLP-1 receptors in the same reward circuitry that lights up when you drink, use drugs, or do anything else that produces a dopamine spike. A comprehensive review in Pharmacological Research found that GLP-1 agonists appear to dampen dopamine release in the nucleus accumbens, which is basically the brain's "more of that, please" center. In animal studies, this translated to less alcohol intake, less cocaine seeking, less nicotine consumption.

If your reward system is screaming for a substance and a medication turns the volume down, you experience less craving. Less craving, less consumption.

What Nobody Wants to Talk About

Craving is not the same thing as addiction.

Craving is the neurochemical urge. Addiction is the craving plus the behavioral architecture plus the psychological infrastructure plus the relational patterns plus, in most cases, one or two co-occurring psychiatric conditions.

The coworker who stopped wanting wine on Ozempic? Maybe she was an early-stage heavy drinker whose only clinical issue was overconsumption. That’s a real population of people. For those people, a medication that dials down the reward response might be sufficient.

But for those with untreated alcohol addiction, just taking Ozempic won’t cut it. We’re talking about people who are numbing grief, or avoiding conflict, or maintaining the one coping mechanism that reliably gets them through the evening. The drinking is the visible part. Underneath it is a root system that a dopamine modulator cannot reach.

You can take away the craving for alcohol and still have a person who does not know how to sit with discomfort. Who has never processed the thing that happened twenty years ago. Whose marriage has been slowly restructuring itself around the drinking for so long that sobriety, without therapeutic support, actually destabilizes the relationship further.

So, Should You Try It?

It depends on what you are dealing with, and most people do not know the full scope of that until someone qualified takes a careful look.

If your relationship with alcohol is primarily a craving problem, and there is no co-occurring depression, no trauma history, no relational wreckage, no identity entanglement with drinking, then yes, a pharmacological intervention might be a reasonable starting point. Talk to a psychiatric provider who can evaluate whether that is actually your clinical picture or whether it is the picture you would prefer to have.

If your drinking is woven into how you manage stress, how you relate to your partner, how you decompress from work, how you avoid the thoughts that come up when the house gets quiet, then a medication that reduces craving is useful the way ibuprofen is useful before physical therapy. It makes the work more tolerable but it’s not the work.

The best use of GLP-1 agonists, if the research continues to hold, will be inside comprehensive outpatient treatment. Medication management alongside therapy. Craving reduction alongside behavioral restructuring. Pharmacology alongside the slow, uncomfortable, irreplaceable process of figuring out who you are when you are not drinking.

That combination is where the real promise lives. Not in replacing one with the other.

What Worries Me

What worries me is the narrative, not the medication. The idea that addiction can be solved with a prescription appeals to something deep and very human: the desire for a fix that does not require you to sit in a room and talk about hard things.

Semaglutide might become a genuinely important tool for treating alcohol use disorder. I hope it does. We need more pharmacological options. What we do not need is another reason for people to believe they can skip the part of recovery that actually changes their lives.

If you are trying to figure out whether your drinking is a craving problem, a clinical problem, or both, contact Attune Health & Wellness at 520-556-7227. A conversation with someone who can see the full picture is worth more than a headline.